Search

Your search keyword '"Eiger, D"' showing total 15 results
Start Over Author "Eiger, D" Publisher elsevier b.v.
15 results on '"Eiger, D"'

2. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Author

Eiger, D., Maurer, C., Brandao, M., Aftimos, P.G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M., and Buisseret, L.

Subjects
*METASTATIC breast cancer, *TRIPLE-negative breast cancer, *CANCER chemotherapy
Published
2020
Full Text
View/download PDF

6. 195TiP SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Author

Maurer, C, Eiger, D, Velghe, C, Aftimos, P G, Maetens, M, Gaye, J, Paesmans, M, Ignatiadis, M, Piccart, M, and Buisseret, L

Subjects
*PACLITAXEL, *CARBOPLATIN, *THERAPEUTICS, *PROGRESSION-free survival, *IMMUNOGLOBULINS, *METASTATIC breast cancer
Published
2019
Full Text
View/download PDF

8. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Author

Brandão, M, Caparica, R, Eiger, D, and Azambuja, E de

Subjects
*GENETIC mutation, *BREAST cancer, *BIOMARKERS, *BIOLOGICAL tags, *CANCER patients, *ESTROGEN, *ESTROGEN antagonists
Abstract

In this review, we discuss biomarkers of response and resistance to PI3K inhibitors (PI3Ki) in estrogen receptor-positive breast cancer, both in the early and advanced settings. We analyse data regarding PIK3CA mutations, PI3K pathway activation, PTEN expression loss, Akt signalling, insulin levels, 18FFDG-PET/CT imaging, FGFR1/2 amplification, KRAS and TP53 mutations. Most of the discussed data comprise retrospective and exploratory studies, hence many results are not conclusive. Therefore, among all of these biomarkers, only PIK3CA mutations have proved to have a predictive value for treatment with the α-selective PI3Ki alpelisib (SOLAR-1 trial) and the β-sparing PI3Ki taselisib (SANDPIPER trial) in the advanced setting. Since the accuracy of current individual biomarkers is not optimal, a composite biomarker, including DNA, RNA and protein expression data, to more precisely assess the PI3K/AKT/mTOR pathway activation status, may arise as a promising approach. Finally, we describe the rational for new combination therapies involving PI3Ki and anti-HER2 agents, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors or new endocrine treatments and discuss the ongoing trials in this field. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. Corrigendum to "Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials": Annals of Oncology 2020; volume 31, supplement 2; s71 (abstr. 153P)

Author

Franzoi, M.A., Ameye, L., Eiger, D., Piccart, M., Brandão, M.D.R.A., Pondé, N., Desmedt, C., Di Cosimo, S., Paesmans, M., Caparica, R., Kotecki, N., Lambertini, M., De Angelis, C., Awada, A.H., and de Azambuja, E.

Subjects
*BODY mass index, *METASTATIC breast cancer, *HORMONE therapy
Published
2020
Full Text
View/download PDF

10. 153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials.

Author

Franzoi, M.A., Ameye, L., Eiger, D., Piccart, M., Brandão, M.D.R.A., Pondé, N., Desmedt, C., Di Cosimo, S., Paesmans, M., Caparica, R., Kotecki, N., Lambertini, M., De Angelis, C., Awada, A.H., and de Azambuja, E.

Subjects
*METASTATIC breast cancer, *BODY mass index, *CANCER hormone therapy, *CLINICAL trials, *DATA analysis
Published
2020
Full Text
View/download PDF

11. VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC).

Author

Huober, J., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Graupner, V., Eiger, D., Henschel, V., Gochitashvili, N., Lambertini, C., Restuccia, E., and Zhang, H.

Subjects
*TRASTUZUMAB, *CANCER chemotherapy, *BREAST cancer, *HER2 protein, *RANDOMIZED controlled trials
Published
2021
Full Text
View/download PDF

14. 188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis.

Author

Brandão, M.D.R.A., Bruzzone, M., Franzoi, M.A., de Angelis, C., Eiger, D., Caparica, R., Dauby, N., Ceppi, M., Piccart, M., Carrilho, C., Lunet, N., Buisseret, L., de Azambuja, E., and Lambertini, M.

Subjects
*HIV infections, *BREAST cancer, *ESTROGEN receptors, *CANCER-related mortality, *SYSTEMATIC reviews
Published
2020
Full Text
View/download PDF

15. 84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial.

Author

De Caluwe, A., Buisseret, L., Poortmans, P., Sotiriou, C., Larsimont, D., Van Gestel, D., Laragione, A., Desmet, A., Van Den Begin, R., Philippson, C., Eiger, D., Piccart, M., Romano, E., and Ignatiadis, M.

Subjects
*BREAST cancer treatment, *NEOADJUVANT chemotherapy, *IMMUNE checkpoint inhibitors
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results